Partner With Us NRI

Tatva Chintan Pharma Chem Ltd share Price Today

Company details

6M Return -29.40%
1Y Return -39.68%
Mkt Cap.(Cr) 2,503.88
Volume 48,464
Div Yield 0.18%
OI Chg %
Volume 48,464

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Specialty Chemicals company Tatva Chintan Pharma Chem announced Q1FY24 results:

  • Revenue from operations of Rs 1,143.64 million in Q1FY24 compared to Rs 884.02 million in Q1FY23, up 29.37% YoY
  • EBITDA (Excl. other income) of Rs 213.43 million in Q1FY24 compared to Rs 152.17 million in Q1FY23, up 40.26% YoY
  • EBITDA Margin of 18.66% in Q1FY24 compared to 17.21% in Q1FY23 
  • Profit before tax of Rs 134.20 million in Q1FY24 compared to Rs 136.95 million in Q1FY23, down 2.01% YoY
  • Profit after tax of Rs 95.04 million in Q1FY24 compared to Rs 97.97 million in Q1FY23, down 2.99% YoY
  • PAT margin of 8.31% in Q1FY24 compared to 11.08% in Q1FY23 
  • Cash profit of Rs 155.16 million in Q1FY24 compared to Rs 121.3 million in Q1FY23, up 27.91% YoY

Commenting on the results, Chintan Shah, Managing Director said, "I am pleased to inform you that TATVA CHINTAN has begun this financial year on a satisfactory note, in line with our expectations and we expect the improvement to gradually continue over the coming quarters. The year has started with better off-take and a favorable product mix translating into better numbers for this quarter.

During this quarter, the company has reported revenue from operations of Rs 1,144 million, a growth of 29% YoY from Rs 884 million. EBITDA during the quarter was at Rs 213 million, a growth of 40% YoY from Rs 152 million. EBIDTA margins were at 18.7% v/s 17.2% in Q1FY23. The inventory (other than spares and packing materials) at consolidated levels has come down by nearly Rs 125 million from Rs 1,325 million as of March 2023 to Rs 1,200 million as of June 2023. The logistic costs have steadily reduced to realistic levels which has come as a breather. Also, the price reduction in the chemical space seems to have lost pace and the prices have begun to stabilize in the past few weeks.

I am quite happy and proud, to inform you that we successfully commenced commercial production from the newly expanded facility at Dahej SEZ. With this the installed reactor capacity increased to 500KL from 294KL and assembly lines increased from 27 to 39."




Result PDF

View Other Company Results

Tatva Chintan Pharma Chem Ltd shares SWOT Analysis

Strengths (6)

  • Rising Net Cash Flow and Cash from Operating activity
  • Company with Low Debt
  • Increasing Revenue every quarter for the past 2 quarters

Weakness (10)

  • MFs decreased their shareholding last quarter
  • Inefficient use of capital to generate profits - RoCE declining in the last 2 years
  • Inefficient use of shareholder funds - ROE declining in the last 2 years

Opportunity (0)

Data not found

Threats (2)

  • High PE (PE > 40)
  • RSI indicating price weakness

Resistance and support

R1 1,109.6
R2 1,148.9
R3 1,198.7


S1 1,020.5
S2 970.7
S3 931.4
Delivery and volume
DAKSHA DUSHYANT PATEL Bulk Purchase 2023-09-06 1646.03 124000 BSE
SHEKHAR RASIKLAL SOMANI Bulk Sell 2023-09-06 1647.83 233767 BSE
DARSHANA NITINKUMAR SHAH Bulk Sell 2023-09-06 1639.6 233766 BSE
Name Category Shares
Shekhar Rasiklal Somani PROMOTER 23.07%
Chintan Nitinkumar Shah PROMOTER 20.94%
Ajay Mansukhlal Patel PROMOTER 17.1%
Priti Ajay Patel PROMOTER 3.85%
Ajay Mansukhlal Patel (HUF) PROMOTER 3.06%
Chintan N Shah (HUF) PROMOTER 1.91%
Shital Chintan Shah PROMOTER 0.99%
Kajalben Shekharkumar Somani PROMOTER 0.93%


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Tatva Chintan Pharma Chem Ltd Stocks COMPARISON

Financials( in Cr) Tatva Chintan Pharma Chem Ltd Pidilite Industries Ltd SRF Ltd Linde India Ltd Deepak Nitrite Ltd
Price 1,070.40 3,108.90 2,367.65 7,884.00 2,899.60
% Change -7.69 -1.67 -1.35 -9.18 6.41
Mcap Cr 2,503.88 158,121.45 70,183.07 67,237.91 39,548.51
Revenue TTM Cr 423.61 12,382.99 13,138.52 2,768.67 7,681.83
Net Profit TTM Cr 45.49 1,747.42 1,335.71 434.09 810.89
PE TTM 96.20 88.72 57.14 156.57 54.35
1 Year Return -39.68 19.76 8.22 83.07 45.94
ROCE 8.34 29.30 12.52 17.04 21.56
ROE 9.21 22.37 12.25 13.14 16.38

Equity Capital: 514.80 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 7,979.66 51,130.08
LAST 3M 85,790.28 63,355.68
LAST 6M 176,360.83 62,258.99
LAST 12M 304,634.27 91,810.54
Tatva Chintan Pharma Chem Limited - Investor Presentation

Jul 24, 2024 l NSE Announcement

NSE Board Meetings Forthcomming

Jul 24, 2024 l NSE Board Meetings Forthcomming

Board Meeting for Today

Jul 24, 2024 l Board Meetings for Today

Date Action Type Ratio
Sep 08, 2023 Dividend 20
Sep 08, 2022 Dividend 20

Tatva Chintan Pharma Chem Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • The Company was formerly incorporated as Tatva Chintan Pharma Chem Private Limited in India on 12 June 1996 under the Companies Act 2013. The status of the Company got converted from Private Limited into a Public Limited Company effective from 27 January 2021 and consequently, the name of Company also changed from `Tatva Chintan Pharma Chem Private Limited` to `Tatva Chintan Pharma Chem Limited`. The Company is promoted by Mr. Chintan Nitin Kumar Shah, Mr. Ajay Kumar Mansukhlal Patel and Mr. Shekhar Rasiklal Somani. The Company is primarily engaged in manufacturing and selling of specialty chemicals, Pharma & Agro intermediates and Quaternary Ammonium Compounds (Quats). The Company is a globally recognized specialty chemical player with several market leading products in its portfolio. Considering the wide application of products, the Company supply products to leading global companies across diverse industries, like automotive, petroleum, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal care and flavor and fragrances with over 1300 customers. Apart from customers in India, the Company export products across the globe including USA, China, Germany, Japan, South Africa and UK. The Company operate through two world class manufacturing facilities located at Dahej and Ankleshwar in Gujarat both of which are strategically located very close to the Hazira Port. These units provide the Company cost and logistics advantage and enabling seamless export and import operations. The Company`s manufacturing facilities obtained ISO 9001:2015 and 14001:2015 certification for robust quality management systems. Employing modern equipment like reactors, assembly lines, ANFDs, centrifuges and RCVDs, enabled the Company to undertake multiple chemistry process. The Company successfully established an integrated model comprising world class manufacturing infrastructure, complex & chemical processes, warehousing facilities and technically sound R&D capabilities, which enables to achieve high operational efficiency and quality, to innovate & customize and to ensure sustainable operations with wide offerings. The Company has sophisticated quality control lab equipped with modern analytical equipment, enabling it to detect impurities upto PPM levels and achieve `ultra-pure`grade certification. The Company Promoters identified an opportunity in manufacturing Phase Transfer Catalyst (PTC), which is a niche segment within the specialty chemicals space. With PTC as the base, the Company have marked presence in the entire value chain including PTC, Structure Directing Agents (SDA), Electrolyte Salts (ES) and Pharmaceutical and agrochemical intermediates and other specialty chemicals (PASC). The Company have a dedicated Department of Scientific and Industrial Research (DSIR) approved R&D centre at its Vadodara facility where qualified and experienced in-house R&D team focus on development of new products and improvement in current manufacturing processes. The Company is having modern systems and analytical development laboratory with state-of-the-art instrumentation. In 2004, the Company received licence from the FDA, Gujarat at its Ankleshwar manufacturing plant. In 2007, the Company commenced Ankleshwar manufacturing facility and increased the expansion of manufacturing capacity. In 2011, the Company started commercial manufacturing of Structure Directing Agents (SDA). In 2015, the Company was accredited Appreciation Certificate for the Ankleshwar Plant from the Office of the Chief Commission of Central Excise, Customs & Service Tax, Vadodara Zone for its contribution to revenue and voluntary compliance with tax laws. The Company achieved revenue of nearly Rs 1 bn. The Company established a warehousing plant in The Netherlands. Tatva Chintan USA Inc. was incorporated as a wholly owned Subsidiary of TCPCL. In 2016, the Company was accorded the status of a two-star export house for the Ankleshwar plant from the Directorate General of Foreign Trade (DGFT), Ministry of Commerce and Industry (MoCI), Government of India (GoI). In 2017, manufacturing plant was established in Dahej, Gujarat. In 2018, the R&D facility was set up in Vadodara. Tatva Chintan Europe BV, was incorporated as wholly owned Subsidiary of the Company in year 2019. In FY 2019-20, the Company`s Ankleshwar unit was converted to a zero liquid effluent discharge facility. The products proved efficiency to ensure lower by-products and waste generation in chemical processes. Additionally, the Company participated in the ` Together for Sustainability` initiatives whereby sustainability sourcing practices of chemical suppliers, like ecological and social aspects were assessed. Under this initiative, the Company involved Ecovadis to audit sustainability practices and performance, the results of which were above the industry average. This created a robust initiative and focused on retaining key customers who consider sustainability an important parameter to do business. In 2020, the Company achieved another Rs 2 billion revenue. In 2021, the manufacturing capacity at Dahej facility in Gujarat increased giving rise to aggregate installed reactor manufacturing capacity of the Company from 160 KL and 10 Assembly Lines to 280 KL and 17 Assembly Lines respectively. During the year 2021, the Company had issued 12,052,500 Equity Shares as Bonus Shares to all the existing shareholders of the Company in the ratio of 1.5:1 vide Board Resolution dated 03 March 2021 which was passed pursuant to passing of Special Resolution by Shareholders in ExtraOrdinary General Meeting held on 27 January 2021 against existing 8,035,000 Equity Shares.

Registered Address

No 502/17 GIDC Estate, Ankleshwar, Bharuch, Gujarat, 393002

Tel : +91-75730-46951/46952
Email : cs:tatvachintan.com
Website : http://www.tatvachintan.com

Link Intime India Pvt Ltd

AGM Date (Month) : Oct
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 543321
Book Closure Date (Month) : Sep
BSE Group : B
ISIN : INE0GK401011

FAQ’s on Tatva Chintan Pharma Chem Ltd Shares

You can buy Tatva Chintan Pharma Chem Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Tatva Chintan Pharma Chem Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jul 24, 2024 03:55 PM the closing price of Tatva Chintan Pharma Chem Ltd was Rs.1,070.40.

The latest PE ratio of Tatva Chintan Pharma Chem Ltd as of Jul 24, 2024 03:55 PM is 96.20

The latest PB ratio of Tatva Chintan Pharma Chem Ltd as of Jul 24, 2024 03:55 PM is 0.29

The 52-week high of Tatva Chintan Pharma Chem Ltd share price is Rs. 1,772.40 while the 52-week low is Rs. 956.70

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jul 24, 2024 03:55 PM, the market cap of Tatva Chintan Pharma Chem Ltd stood at Rs. 2,503.88 Cr.

Download App

Download Our App

Play Store App Store
market app